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Expression of the Collagen VI a5 and a6 Chains
in Normal Human Skin and in Skin of Patients
with Collagen VI-Related Myopathies
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Rosa Curci1, Stefano Squarzoni1, Alessandra Zamparelli1, Elena Martoni4, Luciano Merlini4,
Mats Paulsson2,5,6, Paolo Bonaldo3 and Raimund Wagener2
Collagen VI is an extracellular matrix protein with critical roles in maintaining muscle and skin integrity and
function. Skin abnormalities, including predisposition to keratosis pilaris and abnormal scarring, were
described in Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) patients carrying
mutations in COL6A1, COL6A2, and COL6A3 genes, whereas COL6A5, previously designated as COL29A1, was
linked to atopic dermatitis. To gain insight into the function of the newly identified collagen VI a5 and a6 chains
in human skin, we studied their expression and localization in normal subjects and in genetically characterized
UCMD and BM patients. We found that localization of a5, and to a lesser extent a6, is restricted to the papillary
dermis, where the protein mainly colocalizes with collagen fibrils. In addition, both chains were found around
blood vessels. In UCMD patients with COL6A1 or COL6A2 mutations, immunolabeling for a5 and a6 was often
altered, whereas in a UCMD and in a BM patient, each with a COL6A3 mutation, expression of a5 and a6 was
apparently unaffected, suggesting that these chains may substitute for a3, forming a1a2a5 or a1a2a6
heterotrimers.
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INTRODUCTION
Collagen VI is a functionally important extracellular matrix
protein expressed in many tissues, including skeletal muscle
and skin. It was long considered to consist of three genetically
distinct a-chains (a1, a2, a3), secreted into the extracellular
matrix where they form an extended microfilamentous
network. Mutations in the COL6A1, COL6A2, and COL6A3
genes cause Ullrich congenital muscular dystrophy (UCMD)
and Bethlem myopathy (BM). Although the muscle pheno-
type is predominant, various skin changes have been
described in collagen VI-related disorders, including a
predisposition for keratosis pilaris (follicular keratosis),
abnormal scarring, such as keloids and ‘‘cigarette paper’’
scars, rough or dry skin, and striae rubrae (Pepe et al., 2002;
Jimenez-Mallebrera et al., 2006; Lampe et al., 2008; Nadeau
et al., 2009). In addition, a group of Indian UCMD patients
shows soft velvety skin on the palms and soles that totally
lack major creases and instead have fine mesh-like lines
(Nalini et al., 2009).
Recently, three new collagen VI chains were identified,
a4, a5, and a6, that are encoded by distinct genes, COL6A4,
COL6A5, and COL6A6 (Fitzgerald et al., 2008; Gara et al.,
2008). These chains are composed of seven N-terminal von
Willebrand factor A domains, a collagen triple helical
domain and a C-terminal non-collagenous domain contain-
ing two or three C-terminal von Willebrand factor A domains
and one or two unique sequences. In addition, a4 contains a
Kunitz domain. Their triple helical domains are most similar
to that of a3, and, in general, the recently identified chains
resemble this chain. Indeed, Col6a1 null mice do not deposit
the new chains in the extracellular matrix, showing that
assembly and secretion of these requires the presence of a1
and implying that the new chains may substitute for a3,
probably forming a1a2a4, a1a2a5, or a1a2a6 heterotrimers
(Gara et al., 2008). This is in contrast to assembly studies
using transfected cells, in which only a4, but not a5 and a6,
was found to be able to form heterotrimers that are secreted
(Fitzgerald et al., 2008). In humans, COL6A4 is disrupted by a
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chromosome break (Fitzgerald et al., 2008; Gara et al., 2008;
Wagener et al., 2009) as a consequence of a large-scale
pericentric inversion on chromosome 3 and, interestingly, the
50 end of the split gene was linked to a predisposition for
osteoarthritis (Miyamoto et al., 2008; Wagener et al., 2009).
In humans, COL6A6 is expressed in a wide range of fetal and
adult tissues, whereas COL6A5 expression is restricted to a
few sites, including lung (Fitzgerald et al., 2008) and skin
(So¨derha¨ll et al., 2007). The expression of the newly
identified chains was yet not studied in detail, although
reverse transcription-PCR revealed differences between
human and mouse (So¨derha¨ll et al., 2007; Fitzgerald et al.,
2008; Gara et al., 2008). Human a5 was found to be
localized in the outer epidermis and COL6A5 has been
associated with atopic dermatitis and designated COL29A1
(So¨derha¨ll et al., 2007). Atopic dermatitis patients were found
to lack collagen VI a5 expression in the outer epidermis
(So¨derha¨ll et al., 2007). This was proposed to lead to a loss of
epidermal integrity that may facilitate the antigen penetration
through the skin. However, in a genome-wide association
study in 939 affected individuals, COL6A5 did not show
linkage to atopic dermatitis (Esparza-Gordillo et al., 2009),
whereas in another study a polymorphism of COL6A5
was associated with atopy, but this association could not be
consistently replicated (Castro-Giner et al., 2009). To gain
insight into the function of the newly identified a5 and a6
chains in human skin and their potential role in pathology,
we studied their expression and deposition in normal subjects
and UCMD and BM patients.
RESULTS
Collagen VI a5 and a6 show a more restricted localization
pattern in human skin than the homologous a3
Immunofluorescence microscopy of normal skin sections
labeled with an antibody against collagen VI a3 showed
staining throughout the dermis (Figure 1a and d), whereas
labeling with antibodies against collagen VI a5 and a6
revealed a more restricted localization pattern. Collagen VI
a5 appeared mainly expressed at the papillary dermis
(Figure 1b and e), with a more intense labeling just below
the dermal–epidermal junction. Here, the expression of
collagen VI a6 was much weaker and discontinuous (Figure
1c and f). In contrast, a5 and a6 were both strongly expressed
around blood vessels at the interface between the papillary
dermis and the reticular dermis, but not around the annexes
of the deeper layers of the skin (Figure 1b and c). This pattern
was confirmed by double labeling with antibodies against
laminin a5, a marker for basement membranes (Figure 1).
De-masking experiments revealed that the detection of the
newly identified collagen VI chains in very restricted areas is
not caused by a hindered accessibility of the antibodies
elsewhere (Supplementary Figure S1 online). No collagen VI
was detected in the epidermis, in clear contrast to the
reported expression of collagen VI a5 in the outer epidermis
(So¨derha¨ll et al., 2007). Immunoelectron microscopy analysis
with antibodies against either collagen VI a3, a5, or a6
(Figure 2) confirmed the localization detected by immuno-
fluorescence. In the papillary dermis, a5 and a3 colocalize
with banded collagen fibrils. However, although a5 was
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Figure 1. Collagen VI a chain distribution in normal human skin. Analysis of skin sections from a healthy donor with a mAb against collagen VI a3 (a, d) or
polyclonal antibodies against collagen VI a5 (b, e) or a6 (c, f) (red). Sections were double labeled with an antibody against laminin a5 (green), as a marker
of basement membranes. Collagen VI a3 shows a broad distribution in the papillary and reticular dermis, including vasculature and nerves, and hypodermis.
In contrast, collagen VI a5 is localized in the papillary dermis, close to the dermal–epidermal junction, and around some vessels of the reticular dermis. a6
appears around the vessels of the papillary and reticular dermis, with a weaker and discontinuous labeling below the dermal–epidermal junction. a, b, c and d, e,
f are at the same magnification. Bar¼ 100mm.
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clearly detected along longitudinally sectioned fibrils (Figure
2b and c), a3 was also visible in areas where fibrils were
cross-sectioned (Figure 2a). None of the antibodies labeled
the epidermis, the basement membrane of dermal–epidermal
junctions, or anchoring plaques, which are connected to the
basement membrane through anchoring filaments (Figure 2).
For a6, only a weak labeling was found in the papillary
dermis, where few gold particles, associated with collagen
fibrils, were detected (Figure 2d). Although all chains were
detected around the wall of blood vessels of the papillary
dermis, these showed a different distribution (Figure 2e–i).
Whereas collagen VI a5 and a6 colocalize with collagen
fibril bundles surrounding vessel walls (Figure 2f and g), a3
was also detected at the vessel endothelium, together with
collagen fibrils reaching the basement membrane (Figure 2e).
The basement membrane underlying the endothelium was
not labeled. The reticular dermis did not show labeling for a5
(Figure 2i) or a6 (not shown), whereas when labeled with the
antibody against a3, bundles of collagen fibrils showed gold
particles at intersections (Figure 2h).
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Figure 2. Ultrastructural localization of collagen VI a chains in normal human skin. (a–d) Normal papillary dermis with collagen VI a3 (a), a5 (b, c), and a6 (d)
antibodies. a3 appears at collagen fibrils of the dermal–epidermal junction (arrows, a). a5 is associated with collagen bundles (b, c, arrows), but absent
from epidermis (k), basement membrane (bm), and anchoring fibrils (af). a6 is sparse in papillary dermis (d, arrows). (e–i) Vessels in papillary (e, f, g) and collagen
bundles in reticular dermis (h, i) with a3 (e, h), a5 (f, i), and a6 (g) antibodies. a3 is associated with collagen fibrils reaching basement membranes (e, arrows)
and with intersecting collagen bundles (h); a5 and a6 with collagen bundles surrounding vessels (f, g, arrows), but not with basement membranes (f, g).
a5 is absent within collagen bundles (i). bm, basement membrane; ec, endothelial cell. Bars¼ 200nm.
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Deposition of a5 and a6 in the skin of patients with
COL6A1, -A2, and -A3 mutations
To assess whether mutations in COL6A1, COL6A2, and
COL6A3 affect the secretion and localization of collagen VI
a5 and a6, we investigated skin biopsies from six UCMD
patients carrying mutations in the three genes (two in
COL6A1, three in COL6A2, and one in COL6A3) and one
BM patient with a recessive mutation in COL6A3 (Table 1,
Supplementary Table S1 online). Immunofluorescence
analysis with an antibody against a3 showed a collagen VI
deficiency in the skin of five patients, ranging from moderate
to severe, whereas UCMD-A1b and UCMD-A2c showed
normal expression (Figure 3). Interestingly, immunolabeling
for a5 showed altered expression only in those patients with
mutations in COL6A1 or COL6A2 where collagen VI a3 was
also affected (Figure 4a and b). In particular, in UCMD-A1a
a5 was reduced at the papillary dermis and around blood
vessels (Figure 4a). The expression of a5 varied in patients
carrying different compound heterozygous mutations in
COL6A2 (Table 1): while in UCMD-A2a a5 was evenly
reduced, in UCMD-A2b the labeling was decreased in some
areas of the papillary dermis, both at the dermal–epidermal
junction and around the vessels (Figure 4a). In contrast,
UCMD-A3 and BM-A3, carrying mutations in COL6A3
(Table 1), showed a5 staining of normal intensity; however,
it appeared more widely distributed in both patients and
particularly in UCMD-A3 (Figure 4a). Moreover, in UCMD-
A1a and UCMD-A2b, double labeling for a3 and a5 revealed
ring-like deposits containing only a5 (Figure 4b). These
deposits, usually detected close to the basement membrane
of the dermal–epidermal junction, showed an irregular shape,
and a variable diameter, ranging from 0.5 to 20 mm and were
absent from normal skin. a6 was reduced in UCMD-A1a, but
largely unaffected in all other patients (Figure 4c). However,
it appeared more widely distributed in patients carrying
mutations in COL6A3. Furthermore, the ring-like deposits
were not detected with the antibody against a6 (not shown).
Western blot analysis of collagen VI a5 and a6 in extracts of
normal and UCMD skin
Skin extracts from healthy donors and UCMD-A1a, UCMD-
A2a, and UCMD-A3 were investigated by SDS–PAGE under
reducing conditions using antibodies against collagen VI a3,
a5, and a6 (Figure 5a). In healthy skin, both a5 and a6 were
detected as major bands slightly above the 260 kDa marker,
consistent with their molecular masses (Figure 5a), whereas
a3 was detected migrating as two major bands below and
above the 260 kDa marker. Only in UCMD patients with an
altered collagen VI expression in immunohistochemistry, a3
was much fainter than in the control and in UCMD-A1a it
was detected only after longer exposure. In contrast, a5
was reduced only in UCMD-A2a. However, a5 reproducibly
showed a higher mobility in UCMD-A1a. The reduction of a5
in UCMD-A2a was evident with both methods, whereas the
weaker signal for a5 in UCMD-A1a in immunohistochemistry
was not evident in western blot. The lower molecular mass of
a5 in UCMD-A1a, possibly due to abnormal processing, may
make the protein more easily extractable.
COL6A5 and COL6A6 transcript levels are differently
modified in the skin of UCMD and BM patients
The amount of collagen VI a5 and a6 transcripts in skin
biopsies from selected patients was evaluated by real-time
PCR, using b-actin as a reference (Figure 5b, Table 1).
Whereas levels of COL6A5 mRNA were similar to controls or
only slightly changed in UCMD-A1a, UCMD-A2a, UCMD-
A2b and BM-A3, COL6A5 mRNA levels were reduced to
20% of UCMD-A3. This indicates that the reduction of a5
seen in UCMD-A2a by immunohistochemistry and western
blot is not due to transcriptional downregulation. In contrast,
the reduction of COL6A5 mRNA in UCMD-A3 did not affect
expression of a5. The collagen VI a6 mRNA level was
reduced to 60% of normal levels in UCMD-A3, but was
significantly upregulated in UCMD-A1a and UCMD-A2a and
unaffected in UCMD-A2b and BM-A3. The upregulation of
COL6A6 mRNA in UCMD-A1a and UCMD-A2a did not lead
to a higher expression of the protein.
DISCUSSION
We describe the expression of the recently identified collagen
VI a5 and a6 chains in human skin and its variations in the
skin of patients suffering from collagen VI-related muscular
dystrophies. The tissue distribution of these chains has so
far not been comprehensively studied. We now show that
collagen VI a5 is found in a very specific zone of the papillary
dermis, just below the basement membrane. This is in clear
contrast to an earlier report where collagen VI a5 (called
collagen XXIX by the authors) was found to be located in
the epidermis (So¨derha¨ll et al., 2007). The reason for this
discrepancy is not clear. To our knowledge collagen VI has
never been found in the epidermis by other authors.
Generally, only a few collagens are located in the epidermis,
for example, collagen XXIII (Koch et al., 2006). As the lack of
the new collagen VI chains in the Col6a1 knockout mouse
clearly indicates that they assemble together with a1 and,
probably, a2 to form heterotrimers, an exclusive presence of
collagen VI a5 in the epidermis would be surprising. The
antibody that detected collagen VI a5 in epidermis was raised
against a short peptide sequence and the epidermal staining
could therefore be an artifact. The affinity-purified antibody
used in this study was raised against a large portion of the N-
terminal, non-triple helical domain of collagen VI a5
(domains N2–N6 (Gara et al., 2008)). The specific staining
in a narrow zone just below the basement membrane, which
is reminiscent of that of matrilin-2 (Piecha et al., 2002),
AMACO (Gebauer et al., 2009), or tenascin C (Latijnhouwers
et al., 2000), points to a specialized function of collagen VI
a5 in this zone of the papillary dermis, which is important for
the resistance to tensile stress. Nevertheless, a5 may function
in the maintenance of the barrier function of the skin, as
indicated by the observation of polymorphisms in COL6A5
that were found to be linked to atopic dermatitis (So¨derha¨ll
et al., 2007) or atopy (Castro-Giner et al., 2009). However,
the mechanism by which a5 contributes to the barrier
function would be different from the earlier proposed loss
of epidermal integrity in the outer epidermis of atopic
dermatitis patients (So¨derha¨ll et al., 2007).
102 Journal of Investigative Dermatology (2011), Volume 131
P Sabatelli et al.
Expression of New Collagen VI Chains in Human Skin
Most of the mutations affect the triple helical domain,
except for in BM-A3 and UCMD-A2c where the N8 and C1
domains are affected (Supplementary Table S1 online). The
impact of mutations in COL6A1, COL6A2, and COL6A3 on
the expression of collagen VI a5 and a6 in skin is diverse both
at the level of transcription and translation and strongly
dependent on the specific mutation (Figure 4, Table 1,
Supplementary Table S1 online). This probably reflects the
complex process of assembly of collagen VI microfibrils,
which is prone to perturbations at different levels. As the
incidence of UCMD and BM is low (0.13/100,000 and 0.77/
100,000) (Norwood et al., 2009), resulting in a limited access
to patients, a clear genotype–phenotype correlation was
not obtained. No clear correlations were found between
the steady state levels of COL6A5 and COL6A6 mRNA
and protein expression in selected patients. The lack of an
obvious defect in secretion or assembly in the patients with
mutations in collagen VI a3 (Figure 4) further indicates that
the deposition of a5 or a6 is not dependent on the presence
of a3 and that the new chains may instead substitute for a3 by
the formation of a1a2a5 or a1a2a6-containing collagen VI
molecules. Interestingly, in the UCMD-A3 and BM-A3
patients, a5 and a6 staining is more widely distributed
than in normal skin. This indicates that substitution of a3 by
a5 and/or a6 alters the assembly of collagen VI-containing
microfibrils. The strongly reduced expression of a5 and a6 in
UCMD-A1a carrying a dominant mutation in COL6A1
matches the complete lack of the new collagen VI chains in
Col6a1 knockout mice (Gara et al., 2008) and supports, in
contrast to other reports (Fitzgerald et al., 2008), that also
human collagen VI a5 forms a1a2a5 heterotrimers. However,
as seen in UCMD-A2a and -A2b that carry different
compound heterozygous mutations in COL6A2 (Table 1), it
is evident that the impact on the expression of collagen VI a5
and a6 is highly dependent on the nature of the actual
mutations. Interestingly, whereas the expression of a3 and a5
is clearly reduced in UCMD-A2a, a6 staining remains
unaffected. Owing to the strong reduction of a2 in this
patient, a2 concentration may become rate limiting in the
triple helix formation. Possibly, a6 is preferred to a3 and a5
in this situation. In addition, the strong upregulation of the
COL6A6 mRNA could be responsible for this effect.
Table 1. Collagen VI mutations and phenotypic features
Patient/age
at biopsy
Genomic
mutation1
Skin
phenotype
Collagen VI a3
immuno-
histochemistry/
western blot
Collagen VI a5
immuno-
histochemistry/
western blot
Collagen VI a5
mRNA
(mean DDCt)
Collagen VI a6
immuno-
histochemistry/
western blot
Collagen VI
a6 mRNA
(mean DDCt)
UCMD-A1a/
9 years
Het COL6A1 exon 9
c.921-935 del152
Rough skin,
keratosis pilaris,
hypertrophic scars
Moderately
reduced/severely
reduced
Severely reduced,
ring structures/normal
(higher mobility)
Normal level
(0.98:1)
Severely reduced/
moderately reduced
Increased (3.93:1)
UCMD-A1b/
11 years
Het COL6A1
exon 9 c.850 G4A2
(Gly284Arg)
Keratosis pilaris Not reduced/
reduced
Not reduced/
not reduced
ND Not reduced/
increased
ND
UCMD-A2a/
9 years
Het COL6A2 exon
12 c.1096 C4T;
Het COL6A2 intron 8
c.927+5 G4A3
Keratosis pilaris
and ‘‘cigarette
paper’’ scars
Mildly reduced/
reduced
Severely reduced/
reduced
Slightly increased
(1.85:1)
Normal/normal Increased (3.55:1)
UCMD-A2b/
9 years
Het COL6A2 intron
17 c.1459-2 A4G;
het COL6A2 intron 23
c.1771-1 G4A4
Rough skin,
keratosis pilaris
Severely reduced/
ND
Reduced, ring
structures/ND
Normal level
(1.23:1)
Normal/ND Slightly increased
(1.42:1)
UCMD-A2c/
5 years
Hom COL6A2
intron 25 c.1970-9
G4A3
Rough skin,
keratosis pilaris,
Not reduced/ND Not reduced/ND ND Not reduced/ND ND
UCMD-A3/
9 years
Het COL6A3 intron
16 c.6210+1G4A5
No relevant
changes (keratosis
pilaris reported
in other patients)4
Moderately
reduced/reduced
Normal (widely
distributed)/normal
Strongly reduced
(0.19:1)
Normal/moderately
reduced
Moderately
reduced (0.6:1)
BM-A3/
21 years
Hom COL6A3 exon
5 c.1393 C4T6
Striae rubrae,
keratosis pilaris
Severely reduced/
reduced7
Normal/ND Normal level
(0.77:1)
Widely distributed/
ND
Slightly increased
(1.49:1)
Abbreviation: ND, not determined.
1The DNA mutation numbering is based on complementary DNA sequence with a ‘‘c.’’ symbol before the number with +1 corresponding to the A of the
ATG translation initiation codon in the respective reference sequence (COL6A1 GenBank Refseq NM_001848.2; COL6A2 GenBank Refseq NM_001849.3;
COL6A3 GenBank Refseq NM_004369.2).
2Angelin et al. (2007).
3Martoni et al. (2009).
4Camacho Vanegas et al. (2001).
5Lampe et al. (2008).
6Demir et al. (2002).
7Squarzoni et al. (2006).
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However, it remains unclear why the strong upregulation of
the COL6A6 in UCMD-A1a is not reflected at the protein
level. Similarly, in UCMD-A2b, staining for a3 and a5 is
reduced and a6 is unaffected. Interestingly, as in UCMD-A1a,
ring-like deposits are seen, usually close to the basement
membrane of the dermal–epidermal junction (Figure 4b).
These could represent aggregates of a smaller proportion of
collagen VI a5, which is secreted, but not properly assembled
into microfibrils. In UCMD-A1a, this may correlate with
an increased mobility of collagen VI a5 in western blot
(Figure 5a). The reason for the mobility change remains
unclear; however, alternative splicing, alternate proteolytic
processing, or an altered glycosylation could be responsible.
In contrast to the other patients carrying mutations in
COL6A1 or COL6A2, expression of the newly identified
chains is not affected in UCMD-A1b and in UCMD-A2c
(Figure 4a and c), which adds to the complexity of the
genotype–phenotype correlation. However, a3 is not affected
(Figure 3) and it remains unclear why the formation of
a1a2a3 heterotrimers is still possible. UCMD-A1b carries a
heterozygous mutation in the N-terminal part of the
collagenous domain (Angelin et al., 2007), whereas
UCMD-A2c carries a homozygous mutation in the C1
domain (Martoni et al., 2009). At least in UCMD-A2c the
intact collagenous domain seems to allow the assembly of
a1a2a3 heterotrimers. Accordingly, the formation of a1a2a5-
or a1a2a6-containing collagen VI molecules should also not
be impaired if a5 or a6 substitute for a3. Nevertheless,
also these two patients show a skin phenotype, which could
be the consequence of secreted but malfunctioning collagen
VI molecules.
The mutations in collagen VI a1, a2, and a3 that lead to
muscular dystrophies cause a mitochondrial dysfunction with
spontaneous apoptosis of muscle fibers. Whereas the
pathogenesis of this muscular phenotype has been studied
in great detail (Bernardi and Bonaldo, 2008), the etiology of
the skin phenotypes in these patients is unknown. In this
study we present evidence that collagen VI a5 and a6 are
expressed in dermis and most likely assemble together with
collagen VI a1 and a2. Therefore, a possible contribution of
collagen VI a5 and a6 to the development of the skin
phenotypes has to be considered. The presence of unusual
extracellular aggregates of collagen VI a5 may point to a
possible disease mechanism.
MATERIALS AND METHODS
Expression and purification of recombinant N-terminal collagen
VI a3, a5, and a6 von Willebrand factor A domains
Complementary DNA constructs were generated by reverse tran-
scription-PCR on human placental mRNA. For collagen VI a3
domains N1–N4 and for a5 and a6, the domains N2–N6 were
chosen. Suitable primers introduced 50-terminal NheI or SpeI and 30-
terminal BamHI or XhoI restriction sites (Supplementary Table S2
online). The amplified PCR products were inserted into a modified
pCEP-Pu vector (Tillet et al., 1994) containing an N-terminal BM-40
signal peptide followed by a tandem strepII-tag (Finnis and Gibson,
1997). Recombinant plasmids were introduced into HEK293-EBNA
cells (Invitrogen, Carlsbad, CA) using FuGENE 6 transfection
reagents (Roche, Basel, Switzerland). Cells were selected with
puromycin (1mgml1) and N-terminal tandem strepII-tagged pro-
teins were purified from serum-containing cell culture medium using
a Streptactin column (1.5ml, IBA GmbH, Goettingen, Germany).
Preparation of antibodies against the new collagen VI chains
Purified recombinant collagen VI fragments were used to immunize
rabbits and guinea-pigs. Antisera were purified by affinity chromato-
graphy on a column with antigen coupled to CNBr-activated
Sepharose (GE Healthcare, Little Chalfont, Buckinghamshire, UK)
(Gara et al., 2008).
COL6A3 LAMA5
CTRL UCMD-A1a
UCMD-A2a UCMD-A2b
UCMD-A3 BM-A3
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Figure 3. Collagen VI a3 chain distribution in skin of muscular dystrophy
patients. Analysis of collagen VI in skin sections of six Ullrich congential
muscular dystrophy (UCMD) patients carrying mutations in COL6A1 (UCMD-
A1a and UCMD-A1b), COL6A2 (UCMD-A2a, UCMD-A2b, and UCMD-A2c),
and COL6A3 (UCMD-A3) and one Bethlem myopathy (BM) patient with a
homozygous mutation in the COL6A3 gene (BM-A3), compared with a
healthy donor (CTRL). Staining was performed with antibodies against
collagen VI a3 (green) and laminin a5 (red). Sections of UCMD-A1b and
UCMD-A2c were only stained with antibodies against collagen VI a3. The
images show a reduced expression of collagen VI a3, in four of the six patients
ranging from mild (UCMD-A2a) to moderate (UCMD-A1a and UCMD-A3) or
severe (UCMD-A2b and BM-A3). Bar¼ 100mm.
104 Journal of Investigative Dermatology (2011), Volume 131
P Sabatelli et al.
Expression of New Collagen VI Chains in Human Skin
Patients
Skin biopsies from two healthy subjects, one BM and six UCMD
patients were frozen in isopentane pre-chilled in liquid nitrogen and
stored in liquid nitrogen. All patients were previously diagnosed
by genetic, histochemical, and biochemical analysis, which showed
mutations of the COL6A1, COL6A2, and COL6A3 genes and altered
collagen VI secretion and deposition in skeletal muscle and/or
cultured skin fibroblasts (Table 1). All patients provided informed
consent.
Western blot analysis
Frozen sections (20 mm) were prepared from skin biopsies, dissolved
by incubation for 10minutes at 70 1C in a lysis solution containing
50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM MgCl2, 2% SDS, 1%
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Figure 4. Collagen VI a5 and a6 chain distribution in skin of muscular dystrophy patients. (a) Collagen VI a5 (green) and laminin a5 (red) in skin biopsies from
a normal donor (CTRL) and Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) patients. 4,6-diamidino-2-phenylindole (blue).
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Triton X-100, 0.5mM dithiothreitol, 1mM ethylenediaminetetraacetic
acid, 10% glycerol and protease inhibitors and analyzed by western
blot (Gara et al., 2008).
Immunofluorescence analysis
Frozen sections (7 mm) from skin of two healthy donors and one BM
and six UCMD patients were incubated with an affinity-purified
guinea-pig polyclonal antibody against collagen VI a5, or a
monoclonal collagen VI a3 antibody (Chemicon (Billerica, MA)
clone 3C4), or a rabbit polyclonal antibody against a3. For the
immunofluorescence analysis of a6, frozen sections from healthy
donors and patients were fixed with 2% paraformaldehyde in
phosphate-buffered saline, washed in phosphate-buffered saline and
permeabilized with 0.15% Triton X-100, saturated with 5% normal
goat serum (Sigma, St Louis, MO) and incubated with a rabbit
antibody against a6. All sections were developed with anti-rabbit or
anti-guinea-pig TRITC or FITC-conjugated IgG (DAKO, Glostrup,
Denmark) and double labeled with a mouse mAb against laminin a5
(Chemicon), revealed with anti-mouse FITC- or TRITC-conjugated
secondary antibodies (DAKO).
Immunoelectron microscopy analysis
Skin fragments from one healthy donor were fixed in 4%
paraformaldehyde in phosphate-buffered saline for 1 hour at 4 1C,
washed in phosphate-buffered saline, dehydrated and embedded in
London Resin White. Ultrathin sections were incubated with primary
antibodies, diluted 1/10 in 20-mM Tris-buffered saline, overnight at
4 1C, followed by a 15-nm colloidal gold-conjugated anti-rabbit IgG
antibody (Amersham, Little Chalfont, Buckinghamshire, UK). Sec-
tions were stained with uranyl acetate and lead citrate and observed
with a Philips (Amsterdam, The Netherlands), EM400 transmission
electron microscope operating at 100 kV.
Quantification of COL6A5 and COL6A6 transcripts by
real-time PCR
Total RNA was isolated from skin sections using the RNeasy Kit
(Qiagen, Hilden, Germany) and reverse transcribed using the High
Capacity complementary DNA Reverse Transcription Kit (Applied
Biosystems, Carlsbad, CA), as described (Merlini et al., 2008). To
quantify the steady-state level of COL6A5 and COL6A6 transcripts,
TaqMan expression assays (Applied Biosystems) were used for target
genes (COL6A5 (COL29A1): Hs00542046_m1 exons 35-36;
COL6A6: Hs01029204_m1 exons 12–13) and for b-actin (ACTB
Endogenous Control). Real-time PCR was performed in triplicate on
the Applied Biosystems Prism 7300 system, using 10 ng of
complementary DNA and default parameters. Evaluation of COL6A5
and COL6A6 transcript levels was performed by the comparative Ct
method (DDCt method), in at least two independent experiments.
Complementary DNAs from two control skin sections were utilized
as calibrators and the results were highly similar. Both skin samples
were from children and thereby matching the age of the UCMD
patients. For patient BM-A3, we have also performed comparison
with a skin sample from an adult healthy subject, again with similar
results.
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